TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
We do not offer AOD 9604 to patients at this time
The BPC 157 solution will now be joined by the TB 500 solution in the barrel of the syringe
In addition to continuing reports from Sikiric et al, one group has shown that BPC 157 improves rat tendon growth using a cell model, while another group demonstrated that it is not toxic in dogs
Harmony Health Clinic in Naples views menopause as a whole-body transition
A cloudy result is almost always indicative of a problem during the reconstitution process itself